Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Neta Bar-Hai"'
Autor:
Neta Bar-Hai, Rakefet Ben-Yishay, Sheli Arbili-Yarhi, Naama Herman, Vered Avidan-Noy, Tehillah Menes, Aiham Mansour, Fahim Awwad, Nora Balint-Lahat, Gil Goldinger, Goni Hout-Siloni, Mohammad Adileh, Raanan Berger, Dana Ishay-Ronen
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Cellular plasticity is enhanced by dedifferentiation processes such as epithelial-mesenchymal transition (EMT). The dynamic and transient nature of EMT-like processes challenges the investigation of cell plasticity in patient-derived breast cancer mo
Externí odkaz:
https://doaj.org/article/80c42a7fdd9d4dd1a8f30d553838a539
Autor:
Rakefet Ben-Yishay, Opher Globus, Nora Balint-Lahat, Sheli Arbili-Yarhi, Neta Bar-Hai, Vered Bar, Sara Aharon, Anna Kosenko, Adi Zundelevich, Raanan Berger, Dana Ishay-Ronen
Publikováno v:
Cells, Vol 13, Iss 17, p 1506 (2024)
Epithelial-to-mesenchymal transition (EMT) plays a major role in breast cancer progression and the development of drug resistance. We have previously demonstrated a trans-differentiation therapeutic approach targeting invasive dedifferentiated cancer
Externí odkaz:
https://doaj.org/article/c330496992df471197afa20b6a4dc4ea
Autor:
Neta Bar-Hai, Dana Ishay-Ronen
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Cancer is a systemic heterogeneous disease that can undergo several rounds of latency and activation. Tumor progression evolves by increasing diversity, adaptation to signals from the microenvironment and escape mechanisms from therapy. These dynamic
Externí odkaz:
https://doaj.org/article/1e8205f0c7294ce58e706f6552f55fcb
Autor:
Asher, Neta Bar-Hai, Guy Ben-Betzalel, Ronen Stoff, Shirly Grynberg, Jacob Schachter, Ronnie Shapira-Frommer, Nethanel
Publikováno v:
Cancers; Volume 15; Issue 11; Pages: 3041
Background: Successful treatment with Immune Checkpoint Inhibitors (ICI) requires the balanced activation of the immune system. Over-activation may result in immune-related adverse events (irAEs), which often require steroidal treatment. This study e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=multidiscipl::34bb58d527821464ef7f62347616481c
Autor:
Nethanel Asher, Neta Bar-Hai, Guy Ben-betzalel, Ronen Stoff, Shirly Grynberg, Jacob Schachter, Ronnie Shapira-Frommer
Publikováno v:
Journal of Clinical Oncology. 40:9544-9544
9544 Background: The immune-system manipulation by immune-checkpoint inhibitors (ICI) has led to unprecedented clinical advances in melanoma. The management of the consequent immune-related adverse events (irAEs) is based mostly on steroids and other
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5d939144b23492f4f16af4b746f9f93e
https://doi.org/10.1200/jco.2022.40.16_suppl.9544
https://doi.org/10.1200/jco.2022.40.16_suppl.9544